Lupin has received approval from the CDSCO panel to study a powder for inhalation capsule containing Glycopyrronium Bromide and Vilanterol Trifenatate. This medication is intended for the treatment of respiratory conditions. The company will conduct further research on the product. Cookies are used on the website for analytics and advertising purposes. Continuing to use the site means agreeing to the use of cookies. More information on the use of cookies can be found in the Cookie Policy and Cookie Settings.
Source link
Lupin Gets CDSCO Panel Nod to Study Glycopyrronium Bromide, Vilanterol Trifenatate powder for inhalation in capsule
